Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › KROS

Keros Therapeutics

KROS Rare disease Lead: Phase 3 2 Biotech Distilled articles ↓ 24 filings & releases ↓ Cash $259M (Sep 30, 2026) ↓ 2 verdicts ↓
NeurologyOncology Protein

Market cap $184M 19.6M shares (10-Q, Oct 30, 2026) × $9.36 close Nov 6, 2026

Most recent annual filing: 2026-03-04

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Rinvatercept ALS corporate update2H 2026Rinvatercept ALS corporate update, 2H 2026, routine
  2. Elritercept corporate update~4Q 2026Elritercept corporate update, ~4Q 2026, routine
  3. Capricor deramiocel FDA decisionNov 22, 2026Capricor deramiocel FDA decision, Nov 22, 2026, material
  4. Elritercept RENEW Takeda topline2027Elritercept RENEW Takeda topline, 2027, thesis-defining
  5. Rinvatercept DMD Phase 2 NCT077040991H 2027Rinvatercept DMD Phase 2 NCT07704099, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Discontinued (1)

Capital (as filed)

Cash
$259M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
$3.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$260M cash, runway into the second half of 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Keros Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-07 Watch Keros Therapeutics (KROS) - Scientific Deep Dive for Rinvatercept, Elritercept and Pipeline Products Keros trades below cash with a Takeda Phase 3 royalty attached, but the cash is a budget management guides to spending by H2 2028 on a lead asset with no disclosed human efficacy magnitudes in a class with a poor neuromuscular record.
  2. 2026-11-06 Watch UPDATE: Keros Therapeutics (KROS) - The Q3 Test, Graded Keros passed capital-allocation tests (buyback executed, ATM unused) but the preclinical burn mix is unchanged and no upgrade trigger (positive RENEW or meaningful capital-return commitment) has fired.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)